Stifel analyst Benjamin Burnett raised the firm’s price target on Kinnate Biopharma (KNTE) to $2.59 from $1.50 and keeps a Hold rating on the shares after Xoma (XOMA) announced a deal to acquire Kinnate. The firm thinks the acquisition is a good outcome for Kinnate shareholders and expects the deal to close without issue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KNTE:
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DFS, COF, KNTE
- Kinnate Biopharma downgraded to Market Perform from Outperform at William Blair
- Xoma acquisition boosts royalty growth potential, says H.C. Wainwright
- Kinnate Biopharma’s Strategic Merger with XOMA for Cancer Innovation
- Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share